K-numberK260524
Device nameuMI Panvivo (uMI Panvivo LS); uMI Panvivo (uMI Panvivo); uMI Panvivo (uMI Panvivo S); uMI Panvivo (uMI Panvivo EX); uMI Panvivo (uMI Panvivo ES)
ApplicantShanghai United Imaging Healthcare Co., Ltd.
Product codeKPS
Device classClass II
Decision dateApr 3, 2026
DecisionSubstantially Equivalent
Regulation892.1200
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The uMI Panvivo is a PET/CT imaging system that combines positron emission tomography with computed tomography to provide anatomical and functional images for detecting, diagnosing, staging, and monitoring abnormalities, lesions, tumors, inflammation, and infections across oncology, cardiology, neurology, and other clinical areas. The system can also be used for low-dose CT lung cancer screening and to aid in radiotherapy treatment planning.

Technological characteristics

The proposed uMI Panvivo LS features 360 detector rings with a 1069 mm axial field of view, compared to the predicate's models with 80–240 rings and 235–712 mm axial FOV. Key specifications are substantially identical: same scintillator material (LYSO), detector ring diameter (734 mm), spatial resolution (<3.5 mm at 1 cm), coincidence window (4.9 ns), and advanced functions (Deep MAC, Digital Gating, OncoFocus, NeuroFocus.Brain, uExcel DPR). The increased detector rings and axial FOV improve system sensitivity and scanning efficiency without changing fundamental operating principles.

Test standards cited

ANSI/AAMI ES60601-1:2005, IEC 60601-1-2:2014, IEC 60601-2-44:2009, NEMA NU 2-2018, ISO 14971:2019, ISO 10993-1:2018, IEC 62304:2006, and 21 CFR 820 Quality System Regulation. Performance verification included phantom and clinical image testing per NEMA NU 2-2018 standards for PET performance metrics.

Substantial equivalence argument

The proposed device employs identical basic operating principles, fundamental technologies, detector materials, spatial resolution specifications, and intended clinical use as the predicate device K253564. Differences in detector ring count and axial FOV represent enhancements in sensitivity and scanning range that do not affect safety or effectiveness. Performance testing demonstrates all design specifications are met, and clinical image evaluation by board-certified radiologists confirms image quality is sufficient for diagnostic use. No new safety or effectiveness concerns are raised.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →